Other research analysts also recently issued research reports about the stock. Truist Financial downgraded shares of Aptinyx from a buy rating to a hold rating in a report on Monday. Cowen downgraded shares of Aptinyx from an outperform rating to a market perform rating in a report on Monday. SVB Leerink dropped their price objective on shares of Aptinyx from $4.00 to $3.00 and set an outperform rating on the stock in a report on Friday, August 5th. Piper Sandler downgraded shares of Aptinyx from an overweight rating to a neutral rating and dropped their price objective for the stock from $6.00 to $2.00 in a report on Friday, August 12th. Finally, BMO Capital Markets dropped their price objective on shares of Aptinyx from $6.00 to $2.00 and set an outperform rating on the stock in a report on Monday. Five research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of Hold and an average price target of $3.17.
Aptinyx Stock Performance
Shares of APTX opened at $0.35 on Monday. The company has a market capitalization of $23.82 million, a PE ratio of -0.31 and a beta of 1.24. Aptinyx has a one year low of $0.33 and a one year high of $3.76. The company has a debt-to-equity ratio of 0.39, a current ratio of 16.22 and a quick ratio of 16.22. The company’s fifty day moving average price is $0.53 and its 200 day moving average price is $1.44.
Institutional Trading of Aptinyx
Institutional investors have recently made changes to their positions in the business. Commonwealth Equity Services LLC acquired a new stake in shares of Aptinyx during the 4th quarter valued at about $29,000. Blair William & Co. IL acquired a new position in Aptinyx in the fourth quarter valued at about $51,000. LGL Partners LLC acquired a new position in Aptinyx in the first quarter valued at about $44,000. Jane Street Group LLC boosted its position in Aptinyx by 84.9% in the first quarter. Jane Street Group LLC now owns 38,129 shares of the company’s stock valued at $87,000 after buying an additional 17,504 shares in the last quarter. Finally, Cetera Advisor Networks LLC acquired a new position in Aptinyx in the first quarter valued at about $92,000. 55.97% of the stock is currently owned by institutional investors and hedge funds.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.
- Get a free copy of the StockNews.com research report on Aptinyx (APTX)
- If You Hate Speed Cameras, Then You’ll Like Verra Mobility Stock
- Is Sanofi A Buy, Despite Recent Stumbles?
- Institutional Support For TJX Companies May Cap Gains
- Starbucks Stock, Is Brand Loyalty Enough Reason to Buy
- BJ’s Wholesale Club Pops, Will Costco Be Next?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.